๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjin
Clinical trial register · China

Clinical Trials in Nanjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjin

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
NCT07478484Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection, Metallo-ฮฒ-lactamase-producing
Jing Zhou
Phase 4
144
Nanjin
2026-03-31
Not yet open
Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training
NCT07385885Ultrasound, Needle, Residency, Anesthesiology
Nanjing First Hospital, Nanjing Medical University
Not applicable
30
Nanjin
2026-02-01
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Not yet open
Effectiveness of Extracorporeal Shockwave Therapy Based on Fascial Manipulation Theory for Lateral Epicondylitis
NCT07131423Lateral Epicondylitis (Tennis Elbow)
ZHANG PENG
Not applicable
123
Nanjin
2025-09-25
Recruiting
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
NCT07334483HCC
GrandPharma (China) Co., Ltd.
Phase 2
120
Beijing, Nanjin, Shanghai
2025-08-22
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997Chronic Lymphocytic Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
89
Nanjin
2024-04-16
Recruiting
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Active, closed
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
NCT05797714HBV Infection, Chronic Hepatitis b
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Nanjin.

How many clinical trials are recruiting in Nanjin?

7 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjin), 12 studies
PhaseStudiesRecruitingShare
Phase 35341.7%
Not applicable4133.3%
Phase 22216.7%
Phase 4118.3%

Most active sponsors

Lead sponsors with the most studies (Nanjin)
Lead sponsorStudiesRecruiting
Cytokinetics10
GrandPharma (China) Co., Ltd.11
Institute of Hematology & Blood Diseases Hospital, China11
Jiangsu HengRui Medicine Co., Ltd.10
Jing Zhou11
Nanjing First Hospital, Nanjing Medical University10
Ruijin Hospital10
Shanghai Jiao Tong University School of Medicine11
The First Affiliated Hospital with Nanjing Medical University11
Xiaofeng Chen11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.